Geneva, April 30, 2020: R&D biopharmaceutical companies have brought together their best people, resources and expertise to accelerate the development of new treatments for use in the fight against COVID-19. The R&D biopharmaceutical companies are working with urgency to research and test potential COVID-19 treatments, without compromising safety and quality. To ensure that nobody is...
Read moreIFPMA organized a virtual press briefing with CEOs and top executives who are at the forefront of biopharmaceutical R&D. The briefing was an opportunity to hear directly from the decision-makers.
Read moreThe COVID-19 pandemic has affected millions of people around the world exposed health care systems, broken down economies, and profoundly changed the way of social interactions. This pandemic cannot be tackled alone, and doesn’t leave room for any competing interests. In the words of Dr Tedros Adhanom Ghebreyesus, WHO Director-General, “we will only halt COVID-19...
Read moreThe world’s leading biopharmaceutical companies proclaimed their commitment to a landmark global partnership launched today and designed to accelerate the development and production of safe, effective and affordable therapeutics and vaccines available for all in a way that ensures nobody is left behind in the fight against COVID-19.
Read moreThe biopharmaceutical industry is acutely aware of the enormous responsibility we have to patients and society to engage in unprecedented levels of collaboration to find a solution to COVID-19. We stand ready to bring to this partnership our unique knowledge and expertise in the discovery and development of medicines and vaccines, as well as our...
Read moreThe rapid spread of the COVID-19 pandemic is creating severe disruption to societies and economies, testing health systems worldwide and profoundly impacting the lives of those most vulnerable. On behalf of global biopharmaceutical and medical technologies companies, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the International Council of Biotechnology Associations (ICBA), the Global...
Read moreWe sat down with Dr. Jane Barratt, Secretary General, International Federation of Ageing to discuss the adoption of a life-course approach to health system challenges; the positive impact of adult vaccination across generations; and concrete policy recommendations to prevent the onset of dementia. The Decade of Healthy Ageing(2020-2030) has begun. Why should we adopt an...
Read moreThis was originally published in Devex on Monday, 13 April, 2020. Behind WHO’s new strategy stands great momentum in the global health community to continue to advance the availability of lifesaving vaccines, while ensuring routine immunization can provide an effective platform to expand universal health care coverage. But to ensure vaccines do, in fact, work...
Read moreIn the fight against the novel coronavirus (COVID-19), biopharmaceuticals companies are focusing significant amounts of their resources on the immediate task ahead, which requires pushing the boundaries of science, developing workable solutions and ensuring there is capacity to scale up manufacture once solutions are found, while at the same time ensuring continuity of global supply for critical products. This approach is bearing fruit, with a large number of competitive leads for treatments and vaccines already identified for testing in just a matter of a couple of months.
Read moreThis was originally published in Pharma Boardroom on Wednesday, 1 April, 2020. The CEOs and top executives, David Ricks, Chairman and Chief Executive Officer, Eli Lilly & Co and IFPMA President, Severin Schwan, Chief Executive Officer, Roche, Paul Stoffels, Chief Scientific Officer, Johnson & Johnson, David Loew, Executive Vice-President, Sanofi Pasteur and Rajeev Venkayya, President,...
Read moreThomas Cueni, IFPMA Director General, spoke to BBC Newshour on 19 March about the commitments made by the global pharmaceutical industry in addressing the COVID-19 global health crisis. Industry has the tools and solutions to fight and defeat the novel strain of coronavirus. In this unique situation, industry commits to tackle this issue collaboratively – not just among the industry,...
Read more